UBS Group’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-277
| Closed | -$1.27K | – | 11115 |
|
|
2025
Q3 | $1.27K | Sell |
277
-6,382
| -96% | -$28.3K | ﹤0.01% | 9392 |
|
|
2025
Q2 | $8.26K | Buy |
6,659
+6,518
| +4,623% | +$8.13K | ﹤0.01% | 8960 |
|
|
2025
Q1 | $189 | Buy |
141
+138
| +4,600% | +$212 | ﹤0.01% | 9894 |
|
|
2024
Q4 | $4 | Buy |
+3
| New | +$10 | ﹤0.01% | 9842 |
|
|
2024
Q3 | – | Sell |
-500
| Closed | -$3.75K | – | 10028 |
|
|
2024
Q2 | $3.75K | Buy |
+500
| New | +$6.75K | ﹤0.01% | 8177 |
|
|
2023
Q4 | – | Sell |
-464
| Closed | -$10.6K | – | 9843 |
|
|
2023
Q3 | $10.6K | Buy |
+464
| New | +$24.4K | ﹤0.01% | 7092 |
|
|
2023
Q1 | – | Sell |
-16
| Closed | -$3.24K | – | 10314 |
|
|
2022
Q4 | $3.24K | Buy |
+16
| New | +$3.5K | ﹤0.01% | 9543 |
|
|
2022
Q3 | – | Sell |
-10
| Closed | -$5.84K | – | 10876 |
|
|
2022
Q2 | $7K | Sell |
10
-12
| -55% | -$8.6K | ﹤0.01% | 8530 |
|
|
2022
Q1 | $21K | Buy |
22
+3
| +16% | +$2.54K | ﹤0.01% | 7405 |
|
|
2021
Q4 | $19K | Buy |
19
+15
| +375% | +$21.5K | ﹤0.01% | 7915 |
|
|
2021
Q3 | $7K | Buy |
+4
| New | +$8.9K | ﹤0.01% | 8330 |
|
|
2021
Q2 | – | Sell |
-2
| Closed | -$10K | – | 9786 |
|
|
2021
Q1 | $10K | Hold |
2
| – | – | ﹤0.01% | 7943 |
|
|
2020
Q4 | $13K | Buy |
+2
| New | +$12.7K | ﹤0.01% | 7292 |
|
|
2020
Q3 | – | Sell |
-2
| Closed | -$16K | – | 8379 |
|
|
2020
Q2 | $16K | Buy |
+2
| New | +$23.3K | ﹤0.01% | 6702 |
|
|
2020
Q1 | – | Hold |
0
| – | -$2K | – | 8369 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7850 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7853 |
|
|
2019
Q1 | – | Hold |
0
| – | -$4K | – | 8129 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7641 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7585 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7204 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6952 |
|
|
2017
Q4 | – | Hold |
0
| – | -$16K | – | 8076 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6607 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 5216 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7200 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7521 |
|
|
2015
Q4 | – | Hold |
0
| – | -$1K | – | 8555 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 8239 |
|
|
2015
Q2 | – | Hold |
0
| – | -$6K | – | 8790 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8016 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9271 |
|
Other funds holding SONN
UBS Group's SONN Position: Q4 2025 in Review
UBS Group sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 277 shares — an estimated $1.27K sold.
UBS Group first reported a position in SONN in Q2 2020 and held it in 14 quarters. The position peaked at $21K in Q1 2022. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- UBS Group reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 277 Sonnet BioTherapeutics shares in Q4 2025, an estimated $1.27K.
- UBS Group first reported a position in Sonnet BioTherapeutics in Q2 2020 and held it in 14 quarters.
- UBS Group's Sonnet BioTherapeutics position peaked at $21K in Q1 2022.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.